[go: up one dir, main page]

ECSP10010039A - Composiciones farmacéuticas liofilizadas - Google Patents

Composiciones farmacéuticas liofilizadas

Info

Publication number
ECSP10010039A
ECSP10010039A EC2010010039A ECSP10010039A ECSP10010039A EC SP10010039 A ECSP10010039 A EC SP10010039A EC 2010010039 A EC2010010039 A EC 2010010039A EC SP10010039 A ECSP10010039 A EC SP10010039A EC SP10010039 A ECSP10010039 A EC SP10010039A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
liofilized
administered
orally
administered parenterally
Prior art date
Application number
EC2010010039A
Other languages
English (en)
Inventor
Hans-Peter Zobel
Joseph Lawrence Zielinski
Wei-Qin Tong
Jiahao Zhu
Thitiwan Buranachok-Paisan
Wenlei Jiang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010039A publication Critical patent/ECSP10010039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que incluyen un compuesto terapéutico pobremente soluble en agua, un solvente acuoso, un quelante/antioxidante, un regulador del pH o un componente regulador del pH, y un agente de volumen. Las composiciones farmacéuticas pueden ser oralmente ingeridas o se pueden administrar parenteralmente. Las composiciones farmacéuticas se pueden además liofilizar para formar una torta farmacéuticamente aceptable que se pueda administrar oralmente, por ejemplo como una forma de dosificación oral sólida; o que se pueda reconstituir y administrar parenteralmente, por ejemplo como un solo bolo intravenoso o una infusión intravenosa, o se puede administrar oralmente, por ejemplo como una solución para beber.
EC2010010039A 2007-09-20 2010-03-17 Composiciones farmacéuticas liofilizadas ECSP10010039A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20

Publications (1)

Publication Number Publication Date
ECSP10010039A true ECSP10010039A (es) 2010-04-30

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010039A ECSP10010039A (es) 2007-09-20 2010-03-17 Composiciones farmacéuticas liofilizadas

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017242544B2 (en) * 2016-03-31 2022-11-24 Midatech Ltd. Cyclodextrin-panobinostat adduct

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101139557B1 (ko) * 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
EP2120900A2 (en) * 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer

Also Published As

Publication number Publication date
GT201000062A (es) 2012-03-30
CA2696914A1 (en) 2009-03-26
RU2010115262A (ru) 2011-10-27
PE20090706A1 (es) 2009-07-15
AR068822A1 (es) 2009-12-09
TW200930416A (en) 2009-07-16
TN2010000097A1 (en) 2011-09-26
CO6270207A2 (es) 2011-04-20
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (en) 2009-03-26
MX2010002970A (es) 2010-04-01
CN101801345A (zh) 2010-08-11
JP2010540445A (ja) 2010-12-24
AU2008302273A1 (en) 2009-03-26
KR20100059887A (ko) 2010-06-04
CL2008002786A1 (es) 2009-05-15
MA31744B1 (fr) 2010-10-01
BRPI0817118A2 (pt) 2019-09-24
EP2205222A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CO6241170A2 (es) Administracion de oligonucleotidos antisentido complementarios a la apolipoproteina b humana
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
NZ714963A (en) Compositions and methods for treating anemia
MX2011012122A (es) Derivados de tiofeno.
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
EP3738587A3 (en) Dosage form for insertion into the mouth
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
NZ595767A (en) Composition for the treatment of prostate cancer
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
ECSP10010039A (es) Composiciones farmacéuticas liofilizadas
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
TW200626133A (en) Oral medication for twice-daily administration
RU2011101481A (ru) Способ профилактики острой декомпрессионной болезни
RU2007129408A (ru) Способ выращивания поросят в период откорма
RU2012123302A (ru) Лекарственное средство, предупреждающее предрак и рак простаты, фармацевтическая композиция, активный ингредиент фармацевтической композиции и способ химиопрофилактики рака простаты